Inventor · disambiguated record
Butrus Atrash
Also filed as: ATRASH BUTRUS
12 granted patents·61 citations·filing 1994–2021
90Inventor score
Files withCANCER RESEARCH TECH LTD7BAVETSIAS VASSILIOS1CANCER REC TECH LTD1CANCER RES TECH LTD1SHELDRAKE PETER WILLIAM1
Top patents by PatentIndex Score
12 records- 0193US11897877B2Inhibitor compoundsCANCER RESEARCH TECH LTD·Filed 2021·Granted Feb 13, 2024·2 cites·17 claims
- 0292US9409907B2Inhibitor compoundsCANCER RES TECH LTD·Filed 2013·Granted Aug 9, 2016·14 cites·2 claims
- 0391US9890157B2Inhibitor compoundsCANCER RESEARCH TECH LTD·Filed 2016·Granted Feb 13, 2018·10 cites·15 claims
- 0491US9834552B2Inhibitor compoundsCANCER RESEARCH TECH LTD·Filed 2016·Granted Dec 5, 2017·8 cites·8 claims
- 0588US11046688B2Inhibitor compoundsCANCER RESEARCH TECH LTD·Filed 2019·Granted Jun 29, 2021·2 cites·19 claims
- 0686US10479788B2Compounds that inhibit MPS1 kinaseCANCER RESEARCH TECH LTD·Filed 2018·Granted Nov 19, 2019·4 cites·19 claims
- 0782US9371319B2Pyrrolopyridineamino derivatives as MPS1 inhibitorsBAVETSIAS VASSILIOS·Filed 2012·Granted Jun 21, 2016·8 cites·18 claims
- 0880US9334286B2Pharmacologically active compoundsCANCER REC TECH LTD·Filed 2013·Granted May 10, 2016·4 cites·17 claims
- 0972US8592581B2Trisubstituted purine derivativesSHELDRAKE PETER WILLIAM·Filed 2009·Granted Nov 26, 2013·4 cites·32 claims
- 1071US9895364B2Pharmacologically active compoundsCANCER RESEARCH TECH LTD·Filed 2016·Granted Feb 20, 2018·1 cites·15 claims
- 1154US10188642B2Pharmacologically active compoundsCANCER RESEARCH TECH LTD·Filed 2017·Granted Jan 29, 2019·0 cites·15 claims
- 1241US5424291AIsosteric peptidesFiled 1994·Granted Jun 13, 1995·4 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Butrus Atrash files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →